S-1 adjuvant chemotherapy for advanced gastric cancer
David Kelsen
Correspondence Department of Gastrointestinal Oncology, Memorial Sloan–Kettering Cancer Center, 275 York Avenue, New York, NY 10021, USA
Email kelsend@mskcc.org
This article has no abstract so we have provided the first paragraph of the full text.
In the western world, gastric cancer is a far less common disease than it once was; however, it remains a major global health-care problem. In 2002, over 900,000 patients were diagnosed with gastric cancer, and over 700,000 patients died of this disease.1 The fact that systemic therapy in addition to definitive regional treatment improves outcome for breast and colon cancer is well established, but whether this is also the case for patients with gastric cancers has not been determined.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.